Case Study 1: Bladder Cancer stage 3. Patient with Nagalase Reduction 

Patient Profile: Male, born 1950, diagnosed with carcinoma of the bladder in 2019. 

Treatment: The patient received local chemotherapy solutions initially. GcMAF therapy was introduced later, combined with a tailored I.V protocol. The treatment involved daily injections of GcMAF of 2500ng daily 

Results: Nagalase Levels: The patient’s nagalase levels decreased significantly over 3 months (from 3.10 to 1.40). 

Clinical Outcome: By summer 2020, the bladder was considered clean by the urologist. The patient continued GcMAF treatment and awaited further nagalase testing 3 months later which was normal range. Following an MRI and PET scan remission was confirmed, 

Case Study 2: Bladder Cancer stage 3. Patient with Complete Response. 

Patient Profile: A detailed case study of a bladder cancer patient treated with GcMAF was reported in a clinical setting. 

Treatment: The patient received GcMAF injections as part of their treatment protocol, the patient refused chemotherapy. 

Clinical Outcome: The patient experienced a complete response to the treatment, with no adverse reactions reported. The patient developed mild fatigue and rash during the treatment, but these were manageable. 

These case studies illustrate the potential benefits of GcMAF in treating bladder cancer, highlighting its ability to reduce nagalase levels and improve clinical outcomes with minimal side effects.